Although lapatinib is considered an equipotent inhibitor of HER2 and EGFR, based on data from in vitro kinase assays [14,15], its clinical efficacy to date has been limited to HER2+ breast cancers [16]. This evidence concerns the gene ERBB2 and breast cancer.